Concord Wealth Partners Nektar Therapeutics Transaction History

Concord Wealth Partners

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$3.17 - $6.17 $63 - $123	-20 Closed	0 $0
Q1 2022 Apr 20, 2022	SELL	$4.16 - $13.72 $723 - $2,387	-174 Reduced 89.69%	20 $0
Q4 2021 Jan 21, 2022	BUY	$10.83 - $18.41 $86 - $147	8 Added 4.3%	194 $3,000
Q3 2021 Nov 09, 2021	BUY	$13.07 - $18.84 $941 - $1,356	72 Added 63.16%	186 $3,000
Q2 2021 Jul 29, 2021	BUY	$16.52 - $20.4 $1,057 - $1,305	64 Added 128.0%	114 $2,000
Q1 2021 May 13, 2021	BUY	$16.56 - $25.46 $827 - $1,273	50 New	50 $1,000

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

Stay updated on Concord Wealth Partners with notifications on news.